BMEA Logo

Biomea Fusion, Inc. (BMEA) 

NASDAQ
Market Cap
$233.38M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
208 of 774
Rank in Industry
121 of 433

Largest Insider Buys in Sector

BMEA Stock Price History Chart

BMEA Stock Performance

About Biomea Fusion, Inc.

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Insider Activity of Biomea Fusion, Inc.

Over the last 12 months, insiders at Biomea Fusion, Inc. have bought $155,961 and sold $0 worth of Biomea Fusion, Inc. stock.

On average, over the past 5 years, insiders at Biomea Fusion, Inc. have bought $8.28M and sold $13.28M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Hitchcock Michael J.M. (director) — $100,600. Valle Franco (Chief Financial Officer) — $55,361.

The last purchase of 10,000 shares for transaction amount of $100,600 was made by Hitchcock Michael J.M. (director) on 2024‑09‑30.

List of Insider Buy and Sell Transactions, Biomea Fusion, Inc.

2024-09-30Purchasedirector
10,000
0.029%
$10.06$100,600+0.10%
2024-06-11PurchaseChief Financial Officer
12,509
0.0348%
$4.43$55,361+70.65%
2023-06-01Sale10 percent owner
50,000
0.1638%
$34.56$1.73M-57.40%
2023-05-31Sale10 percent owner
75,000
0.2524%
$33.81$2.54M-55.18%
2023-05-12Sale10 percent owner
25,000
0.0841%
$33.84$846,000-53.60%
2023-05-09Sale10 percent owner
150,000
0.5185%
$34.50$5.18M-53.17%
2023-05-08Sale10 percent owner
100,000
0.3445%
$33.99$3.4M-52.59%
2023-04-20Sale10 percent owner
200,000
0.6723%
$29.12$5.82M-43.70%
2023-03-31Sale10 percent owner
200,000
0.6812%
$31.25$6.25M-45.44%
2023-03-30Purchase
400,000
1.2695%
$30.00$12M-47.04%
2022-11-14Purchasedirector
5,000
0.0169%
$7.93$39,650+88.46%
2022-11-11PurchaseChief Financial Officer
4,100
0.0134%
$7.63$31,286+90.01%
2022-08-16Purchase
30,684
0.1067%
$13.87$425,648-9.74%
2022-07-21Sale
34,658
0.1118%
$11.21$388,516-2.11%
2022-06-24Sale
34,658
0.1168%
$11.76$407,578-5.69%
2022-01-14PurchaseChief Financial Officer
10,000
0.033%
$8.68$86,767-17.39%
2021-09-17Purchasedirector
34,658
0.1193%
$10.96$379,852-20.13%
2021-09-17Purchase10 percent owner
34,658
0.1193%
$10.96$379,852-20.13%
2021-08-23PurchasePresident & COO
24,000
0.0831%
$13.20$316,872-32.89%
2021-08-23PurchaseCEO
24,000
0.0831%
$13.20$316,872-32.89%

Insider Historical Profitability

<0.0001%
Valle FrancoChief Financial Officer
42500
0.1173%
$6.4430+36.31%
Hitchcock Michael J.M.director
15000
0.0414%
$6.4420+88.46%
Stergiopoulos Sotiriosdirector
4400000
12.1417%
$6.4410<0.0001%
Chen Bihua
3570872
9.8538%
$6.4420<0.0001%
A2A Pharmaceuticals, Inc.10 percent owner
3500000
9.6582%
$6.4429<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$80.07M14.95.36M0%+$00.01
State Street$67.06M12.484.49M+232.03%+$46.86M<0.01
Cormorant Asset Management Lp$53.38M9.933.57M0%+$02.49
Laurion Capital Management LP$40.68M7.572.72M-0.56%-$229,990.800.29
Baker Bros Advisors LP$31.53M5.872.11M0%+$00.23
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.